MDT

Medtronic is a diversified medtech incumbent with scale across cardiovascular, neuroscience, medical-surgical, and diabetes, which supports sticky hospital relationships and recurring disposables/service revenue. Recent portfolio streamlining (e.g., combining cardiac surgery and aortic into a cardiovascular surgery business) suggests a push to sharpen execution in slower, complex categories while still funding innovation. Industry demand remains supported by aging demographics, but pricing pressure, procurement (notably China), and innovation cycles in diabetes and structural heart keep competition intense.

Fundamentals improved into FY26: Q3 FY26 revenue was about $9.0B (up 8.7% reported / 6.0% organic) with non-GAAP EPS of $1.36, and Q2 FY26 revenue was $8.961B with gross margin around 60.3% and non-GAAP EPS also $1.36. Management’s FY26 framework has pointed to roughly mid-single-digit organic growth and FY26 non-GAAP EPS guidance around $5.62–$5.66, implying modest operating leverage if mix and productivity hold. Valuation looks full given a mid‑20s P/E cited by market data sources, but the roughly $2.84 annual dividend (about a low‑to‑mid 3% yield) helps support total return.

Over the next 12 months, the key catalyst is the June 3, 2026 Q4/FY26 print and FY27 outlook update, where investors will focus on whether “high single-digit” FY27 EPS growth remains credible and whether margins expand. Upside also hinges on continued recovery in higher-growth franchises (ablation, neuromodulation, spine enabling tech) and avoiding meaningful product disruptions. Risks include FX/tariff noise, China volume-based procurement pressure, and any acceleration in litigation/regulatory overhangs in devices categories.

Recommendation: HOLD. Medtronic offers improving growth and a solid dividend, but with valuation already demanding, the next leg higher likely requires a cleaner FY27 margin-and-growth narrative than the market has recently priced in.